Corsee Sanders
About Dr. Corazon (Corsee) D. Sanders
Dr. Corazon (Corsee) D. Sanders, age 68, has served as an independent non‑executive director of ONC (BeiGene, Ltd.) since August 2020. She holds a B.S. and M.S. in statistics from the University of the Philippines and an M.A. and Ph.D. in statistics from the Wharton Doctoral Program at the University of Pennsylvania, with extensive leadership experience across biotech and pharma operations and clinical development . She is designated independent under Nasdaq and HK Listing Rules, and currently serves in multiple board committees at ONC .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Genentech/Roche | Global Head Clinical Operations; Global Head of Biometrics; Co‑Chair, Portfolio Management Committee | Prior years (dates not specified) | Led global clinical operations and biometrics; portfolio governance |
| Juno Therapeutics Inc. | EVP of Development Operations; Member of Executive Committee | Prior years (dates not specified) | Built development operations; executive governance |
| Celgene Corporation | Strategic Advisor to CMO | 2018–2019 | Corporate clinical strategy support |
| Bristol Myers Squibb Corporation | Transition Advisor | 2019–2020 | Post‑merger transition advisory |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Legend Biotech Corporation | Director | 2020–Present | Not disclosed in proxy |
| Ultragenyx Pharmaceutical Inc. | Director | 2021–Present | Not disclosed in proxy |
Board Governance
- Class and term: Class II director continuing in office until the 2027 annual general meeting .
- Independence: The Board determined all non‑employee directors except two are independent; Sanders is listed as an independent non‑executive director .
- Committee memberships:
- Audit Committee (member; committee chaired by Shalini Sharp; Sanders listed among members) .
- Scientific Advisory Committee (member; co‑chaired by Alessandro Riva and Xiaodong Wang) .
- Commercial and Medical Affairs Advisory Committee (member; chaired by Anthony C. Hooper) .
- Attendance and engagement:
- Board held eight meetings in 2024; each director then in office attended at least 75% of Board and committee meetings on which they served .
- AGM attendance: all then‑serving directors attended the 2024 AGM except Dr. Sanders due to an unavoidable conflict .
- Lead Independent Director: Ranjeev Krishana; executive sessions held at regularly scheduled Board meetings .
Fixed Compensation
| Component | 2024 Amount (USD) | Notes |
|---|---|---|
| Board annual cash retainer | Part of $102,500 total fees | Policy: $65,000 board retainer |
| Committee membership fees | Part of $102,500 total fees | Policy: Audit $17,500; Commercial/Medical $10,000; Scientific $10,000 (non‑chair) |
| Total fees earned | $102,500 | Matches board + 3 committee memberships |
| Stock awards (RSUs) | $199,901 | Annual independent director grant; time‑based vesting |
| Option awards | $199,995 | Annual independent director grant; FMV exercise price policy |
| Total compensation | $502,396 | Sum of fees, RSUs, options |
Policy reference (structure and mix):
- Independent Director Compensation Policy provides $400,000 annual equity at each AGM, split 50% options and 50% RSUs; initial grant also $400,000 (pro‑rated), with time‑based vesting to the next AGM; cash retainers as listed above .
Performance Compensation
- No performance‑based cash bonus or PSU compensation disclosed for independent directors; equity grants for directors are time‑based RSUs and options (not PSUs) per policy .
Other Directorships & Interlocks
| Company | Relationship to ONC | Potential Interlock/Conflict |
|---|---|---|
| Legend Biotech Corporation | Unaffiliated public biopharma board | No ONC related‑party transactions disclosed involving Legend; no interlock noted |
| Ultragenyx Pharmaceutical Inc. | Unaffiliated public biopharma board | No ONC related‑party transactions disclosed involving Ultragenyx; no interlock noted |
- Compensation Committee interlocks: None of the Compensation Committee members (Dugan, Krishana, Yi) had interlocks; Sanders is not on Compensation Committee .
Expertise & Qualifications
- Education: B.S. and M.S. in statistics (University of the Philippines); M.A. and Ph.D. in statistics (Wharton, University of Pennsylvania) .
- Technical/industry expertise: Global clinical operations leadership, biometrics, portfolio management across Genentech/Roche, Juno Therapeutics; strategic advisory at Celgene and BMS; ONC cites her “extensive experience and knowledge in the healthcare sector and scientific and leadership experience” as qualifications for board service .
Equity Ownership
| Metric | Amount |
|---|---|
| Total beneficial ownership (ordinary shares) | 136,500 (<1% of outstanding) |
| Composition detail | 29,900 shares directly held; 106,600 shares issuable within 60 days via options/RSUs |
| Options outstanding (ordinary shares) | 140,751 |
| RSUs outstanding (ordinary shares) | 16,341 |
| Ownership guidelines | Directors must hold equity worth ≥5× board cash retainer; all directors were in compliance as of Dec 31, 2024 |
| Hedging/pledging policy | Hedging and pledging prohibited unless approved; strong insider trading controls |
Governance Assessment
- Committee load and skills alignment: Service on Audit, Scientific Advisory, and Commercial & Medical Affairs aligns with her clinical operations and analytics background; Audit Committee independence affirmed, with robust pre‑approval and oversight practices .
- Attendance: Met minimum engagement threshold (≥75%); missed 2024 AGM due to conflict – not uncommon but should be monitored for future AGM participation as a best‑practice signal .
- Pay mix and alignment: Director pay balances cash retainer and time‑based equity (options/RSUs). Annual director equity is standardized at $400k and vests to next AGM, supporting alignment but not contingent on performance metrics; ownership guideline compliance further supports skin‑in‑the‑game .
- Conflicts/related‑party exposure: No related‑party transactions or consultant conflicts disclosed involving Sanders; ONC’s disclosed related‑party items primarily concern Amgen and Hillhouse‑related entities, with Audit Committee oversight and structural safeguards (e.g., Connected Person Placing Authorization conditions) .
- Shareholder signals: Prior say‑on‑pay approval for NEOs was 88.2% in 2024, indicating generally supportive investor sentiment toward compensation governance, though director pay is separate .
RED FLAGS: None material disclosed specific to Dr. Sanders. Note the missed AGM in 2024; continued monitoring of AGM attendance is advisable . No pledging/hedging, repricing, or related‑party transactions tied to Sanders are disclosed .